TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Na
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Praxis Precision Medicines received FDA Breakthrough Therapy Designation for ulixacaltamide, a T-type calcium channel inhibitor for essential tremor treatment, based on positive Phase 3 Essential3 program results. The company plans to submit a New Drug Application (NDA) in early 2026 following a successful pre-NDA meeting with the FDA.

Insights
PRAX   positive

The company received FDA Breakthrough Therapy Designation, which accelerates development and regulatory review. Positive Phase 3 trial results and successful pre-NDA alignment with FDA support faster advancement toward commercialization. The designation addresses a significant unmet medical need in a large patient population (7 million in the US), representing substantial commercial opportunity.